Robert Orlowski, Deputy Chair of Lymphoma/Myeloma, Vice Chair of MM Research, and Florence Maude Thomas Cancer Research Professor at the University of Texas MD Anderson Cancer Center, shared a post on X:
“Myeloma Paper of the Day:
Novel immune checkpoint inhibitor selectively prevents HLA-E: NKG2A interaction and activates NK cells against tumor cells presenting HLA-E-peptide complexes, potentially minimizing toxicity versus current NKG2A inhibitors.”
Title: HLA-E [pHLA-G] Complex Specific Monoclonal Antibody Enhancing NK Activity in Multiple Myeloma
Authors: Muhammad Abu Ahmad, Olga Radinsky, Bar Kaufman, Kamran Waidha, Eman Gharra, Sharon Dim, Dinesh Babu Manikandan, Noa Ofir, Dirk Jäger, Marten Meyer, Moshe Elkabets, Kerry S. Campbell, Miri Zektser, Roi Gazit, Ory Rouvio, Frank Momburg, Angel Porgador
You can read the Full Article in Blood Advances.
You can find more posts featuring Robert Orlowski in OncoDaily.
